The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
Open accessAbstract
Purpose: The clinical significance of epidermal growth factor receptor variant III (EGFRvIII) expression in glioblastoma multiforme (GBM) and its relationship with other key molecular markers are not clear. We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status. Patients and Methods: The expression of EGFRvIII was assessed by immunohistochemistry in 649 patients with newly diagnosed GBM. These data were then examined in conjunction with the expression of phospho-intermediates (in a subset of these patients) of downstream AKT and Ras pathways and YKL-40 as well as with known clinical risk factors, including the Radiation Therapy Oncology Group's recursive partitioning analysis (RTOG-RPA) class. Results: The RTOG-RPA class was highly predictive of survival in EGFRvIII-negative patients but much less predictive in EGFRvIII-positive patients. These findings were seen in both an initial test set (n = 268) and a larger validation set (n = 381). Similarly, activation of the AKT/MAPK pathways and YKL-40 positivity were predictive of poor outcome in EGFRvIII-negative patients but not in EGFRvIII-positive patients. Pair-wise combinations of markers identified EGFRvIII and YKL-40 as prognostically important. In particular, outcome in patients with EGFRvIII-negative/YKL-40–negative tumors was significantly better than the outcome in patients with the other three combinations of these two markers. Conclusion: Established prognostic factors in GBM were not predictive of outcome in the EGFRvIII-positive subset, although this requires confirmation in independent data sets. GBMs negative for both EGFRvIII and YKL-40 show less aggressive behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression modelling strategies for improved prognostic prediction
Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,798
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Self-citationCurran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
Self-citationEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
RECKLIES, A. D., WHITE, C., & LING, H. (2002) · Biochemical Journal · doi:10.1042/bj20020075 · Cited by 388
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Performance status assessment in cancer patients
Conill, C., Verger, E., & Salamero, M. (1990) · Cancer · doi:10.1002/1097-0142(19900415)65:8<1864::aid-cncr2820650832>3.0.co;2-u · Cited by 361
Proliferation of human malignant astrocytomas is dependent on Ras activation
Guha, A., Feldkamp, M. M., Lau, N., Boss, G., & Pawson, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201455 · Cited by 337
Scott Ph.D., C. B., Scarantino M.D., P. D., Urtasun M.D., Movsas M.D., Jones M.D., Simpson M.D., Fischbach M.D., & Curran Jr., M. D. (1998) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00485-9 · Cited by 323
Moscatello, D. K., Holgado-Madruga, M., Emlet, D. R., Montgomery, R. B., & Wong, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.200 · Cited by 305
Oxaliplatin-related side effects: Characteristics and management
Cassidy, J., & Misset, J.-L. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90016-3 · Cited by 298
Aldape, K. D., Ballman, K., Furth, A., Buckner, J. C., Giannini, C., Burger, P. C., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.7.700 · Cited by 278
Self-citationSimmons, M. L., Lamborn, K. R., Takahashi, M., Chen, P.-Y., Israel, M. A., Berger, M. S., Godfrey, T. E., Nigro, J. M., Prados, M. D., Chang, S. M., et al. (2001) · PubMed · Cited by 278
Self-citationKobayashi, K., Takeda, F., Teramukai, S., Gotoh, I., Sakai, H., Yoneda, S., Noguchi, Y., Ogasawara, H., & Yoshida, K. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00395-x · Cited by 256
Heimberger, A. B., Alexander, L. E. C., Archer, G. E., Hess, K. R., Wikstrand, C. J., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2003) · PubMed · Cited by 234
Self-citationFeldkamp, M. M., Feldkamp, M. M., Lala, P., Lau, N., Roncari, L., Guha, A., Guha, A., & Guha, A. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00034 · Cited by 227
LING, H., & RECKLIES, A. D. (2004) · Biochemical Journal · doi:10.1042/bj20040099 · Cited by 225
Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., & Loeffler, J. S. (2002) · PubMed · Cited by 212
Pelloski, C. E., Mahajan, A., Maor, M., Chang, E. L., Woo, S., Gilbert, M., Colman, H., Yang, H., Ledoux, A., Blair, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1765 · Cited by 207
Self-citationMishima, K., Johns, T. G., Luwor, R. B., Scott, A. M., Stockert, E., Jungbluth, A. A., Ji, X.-D., Suvarna, P., Voland, J. R., Old, L. J., et al. (2001) · PubMed · Cited by 204
Pelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
Self-citationLi, B., Yuan, M., Kim, I.-A., Chang, C.-M., Bernhard, E. J., & Shu, H.-K. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207602 · Cited by 168
Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., & Fry, D. J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70122-x · Cited by 121
Chakravarti, A., Delaney, M. A., Noll, E., Black, P. M., Loeffler, J. S., Muzikansky, A., & Dyson, N. J. (2001) · PubMed · Cited by 111
Perera, R. M., Narita, Y., Furnari, F. B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2653 · Cited by 103
Liu, L., Bäcklund, L. M., Nilsson, B. R., et al. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0700-2 · Cited by 103
Beers, R., Chowdhury, P., Bigner, D. D., & Pastan, I. (2000) · PubMed · Cited by 75
Prognostic relevance of MAPK expression in glioblastoma multiforme
Mawrin, C., Diete, S., Treuheit, T., Kropf, S., Vorwerk, C. K., Boltze, C., Kirches, E., Firsching, R. P., & Dietzmann, K. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.3.641 · Cited by 57
Advances in the biology and treatment of myeloma bone disease.
Berenson, J. R. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34071 · Cited by 30
Rajkumar, S. V., Buckner, J. C., Schomberg, P. J., et al. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00352-6 · Cited by 24
Self-citation
Cited by
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Becker, A., Thakur, B. K., Weiss, J. M., Kim, H. S., Peinado, H., & Lyden, D. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.009 · Cited by 2,003
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Self-citationGlioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Self-citation
Metadata
- Authors
- Pelloski, C. E., Ballman, K. V., Furth, A. F., Zhang, L., Lin, E., Sulman, E. P., Bhat, K., McDonald, J. M., Yung, W. K. A., Colman, H., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M. D., Chang, S. M., Barker, F. G., Buckner, J. C., James, C. D., & Aldape, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-01
- Volume
- 25
- Issue
- 16
- Pages
- 2288-2294
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2121889629
- Cited by
- 311
- References
- 33
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.